- Home
- ROC vs CLNN Comparison
ROC vs CLNN Comparison
Compare ROC & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROC | CLNN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | 82 | 79 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 85.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROC | CLNN |
|---|---|---|
| Price | $5.12 | $6.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $33.75 |
| AVG Volume (30 Days) | 66.3K | ★ 70.3K |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $3.25 |
| 52 Week High | $7.80 | $13.50 |
Technical Indicators
Market Signals| Indicator | ROC | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 56.06 |
| Support Level | $4.42 | $5.39 |
| Resistance Level | $5.32 | $6.63 |
| Average True Range (ATR) | 0.60 | 0.36 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 62.61 | 80.23 |
Price Performance
Historical ComparisonAbout ROC Rank One Computing Corporation Common stock
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.